Low-dose Naltrexone: An Alternative Treatment for Erythrodermic Psoriasis (Abstract)

The LDN Conference 2021: 4th - 6th June 2021

Up to 29 CME Credits Available + Sponsor, Exhibitor and Advertiser Opportunities.  [More Details]

Low-dose Naltrexone: An Alternative Treatment for Erythrodermic Psoriasis

Cureus
24 January 2019
https://www.cureus.com/articles/10833-low-dose-naltrexone-an-alternative-treatment-for-erythrodermic-psoriasis

This clinical case demonstrates the benefits of patient treatment with low-dose naltrexone (LDN) used in erythrodermic psoriasis. A patient with a confirmed history of psoriasis by histopathology was treated with 4.5 mg of LDN during six months follow-up after an erythrodermic psoriasis flare-up. The patient showed significant improvement in her flare-up and psoriasis remission after only three months of 4.5 mg of LDN on a daily basis. Low-dose naltrexone (LDN) has proven to be a great ally in treating erythrodermic psoriasis flare-ups as an alternative treatment with less collateral side effects.